Combination therapy reduces transarterial chemoembolization resistance in advanced hepatocellular carcinoma

doi:10.5306/wjco.v16.i8.109419

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 8

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (171)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-3) series, Tables (1-3) series.

Item

Count

PDF

HTML

Figures (1-3)

Tables (1-3)

Sum=118

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=45

Aug 24, 2025 (publication date) through Aug 23, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Clin Oncol. Aug 24, 2025; 16(8): 109419
Published online Aug 24, 2025. doi: 10.5306/wjco.v16.i8.109419

Open in New Tab Full Size Figure Download Figure

Figure 1 Patient recruitment flowchart for this study. TACE: Transarterial chemoembolization; PD-(L)1: Programmed cell death (ligand) 1; PSM: Propensity score matching.

Open in New Tab Full Size Figure Download Figure

Figure 2 Comparative analysis of therapeutic efficacy between combination group and monotherapy group following three sessions of transarterial chemoembolization.

Open in New Tab Full Size Figure Download Figure

Figure 3 Kaplan-Meier analysis of progression-free survival and overall survival. A and B: Denote the progression-free survival and overall survival of the combination group and monotherapy group, respectively. PFS: Progression-free survival, OS: Overall survival.

Citation: Jiao HY, Yan XM, Li JX, Zhang ZG. Combination therapy reduces transarterial chemoembolization resistance in advanced hepatocellular carcinoma. World J Clin Oncol 2025; 16(8): 109419
URL: https://www.wjgnet.com/2218-4333/full/v16/i8/109419.htm
DOI: https://dx.doi.org/10.5306/wjco.v16.i8.109419